We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sunesis Pharmaceuticals Inc | NASDAQ:SNSS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 5.32 | 4.72 | 4.75 | 0 | 00:00:00 |
From Mar 2020 to Mar 2025
Wells Fargo 2020 Virtual Healthcare ConferenceDate: Thursday, September 10Time: 2:00 PM Eastern Time
Oppenheimer Fall Healthcare Life Sciences & MedTech SummitDate: Tuesday, September 21Time: 4:10 PM Eastern Time
Live webcasts of the events will be available on the Sunesis website at http://ir.sunesis.com. A replay of each will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including first-in-class PDK1 inhibitor SNS-510. SNS-510 is in IND-enabling studies and vecabrutinib is completing a Phase 1b trial in patients with advanced B cell malignancies.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
| Investor and Media Inquiries: | Par Hyare | |
| Maeve Conneighton | Sunesis Pharmaceuticals Inc. | |
| Argot Partners | 650-266-3784 | |
| 212-600-1902 |
1 Year Sunesis Pharmaceuticals Chart |
1 Month Sunesis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
